Table 1.
Updates in WHO/ICC classifications of AML
| WHO 2022 | ICC 2022* | |
|---|---|---|
| AML with defining genetic abnormalities** | APL with PML::RARA fusion | APL with t (15;17) (q24.1;q21.2)/PML::RARA§ |
| APL with other RARA rearrangements§ | ||
| AML with RUNX1::RUNX1T1 fusion | AML with t (8;21) (q22;q22.1)/RUNX1::RUNX1T1§ | |
| AML with CBFB::MYH11 fusion | AML with inv (16) (p13.1q22) or t (16;16) (p13.1;q22)/CBFB::MYH11§ | |
| AML with DEK::NUP214 fusion | AML with t (6;9) (p22.3;q34.1)/DEK::NUP214§ | |
| AML with RBM15::MRTFA fusion | Not recognized | |
| AML with BCR::ABL1 fusion | AML with t (9;22) (q34.1;q11.2)/BCR::ABL1# | |
| AML with KMT2A rearrangement | AML with t (9;11) (p21.3;q23.3)/MLLT3::KMT2A§ | |
| AML with other KMT2A rearrangements§ | ||
| AML with MECOM rearrangement | AML with inv (3) (q21.3q26.2) or t (3;3) (q21.3;q26.2)/GATA2; MECOM (EVI1)§ | |
| AML with other MECOM rearrangements§ | ||
| AML with NUP98 rearrangement | Not recognized | |
| AML with NPM1 mutation | AML with mutated NPM1§ | |
| AML with CEBPA mutation | AML with in-frame bZIP CEBPA mutations§ | |
| AML, myelodysplasia-related† | AML# and MDS/AML§ with mutated TP53 | |
| AML# and MDS/AML§ with myelodysplasia-related gene mutations | ||
| AML# and MDS/AML§ with myelodysplasia-related cytogenetic abnormalities | ||
| MDS/AML NOS§ | ||
| AML with other defined genetic alterations | AML with other rare recurring translocations# | |
| Myeloid proliferations associated with Down syndrome | ||
| AML, defined by differentiation | AML with minimal differentiation | AML NOS# |
| AML without maturation | ||
| AML with maturation | ||
| Acute basophilic leukemia | ||
| Acute myelomonocytic leukemia | ||
| Acute monocytic leukemia | ||
| Acute erythroid leukemia | ||
| Acute megakaryoblastic leukemia | ||
| Myeloid sarcoma | Myeloid sarcoma | |
| Blastic plasmacytoid dendritic cell neoplasm | Blastic plasmacytoid dendritic cell neoplasm |
AML Acute myeloid leukemia, APL Acute promyelocytic leukemia, MDS Myelodysplastic syndrome, bZIP Basic leucine zipper domain, NOS Not otherwise specified, WHO World Health Organization, ICC International Consensus Classification
*Requires mention of qualifiers (Therapy-related, Progressing from MDS, Progressing from MDS/MPN, and/or Germline predisposition)
** ≥ 20% blast cutoff is no longer required for AML with defining genetic abnormalities except for BCR::ABL fusion and CEBPA mutation
† AML, myelodysplasia-related encompasses AML transformation from MDS and MDS/MPN
§Blast cutoff ≥ 10%
#Blast cutoff ≥ 20%